|Peer-Reviewed|December 23, 2020
- January 2021
- Volume 27
- Issue 1
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Advertisement
Articles in this issue
about 5 years ago
ASH 2020: Clinical Updatesabout 5 years ago
ASH 2020: COVID-19 and Hematologyabout 5 years ago
ASH 2020: CAR T-Cell Therapy Updatesabout 5 years ago
ASH 2020: The Next Waveabout 5 years ago
2020 SABCS: Topics in Precision OncologyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
4
Exploring Identity, Appearance Experiences Among Patients With Alopecia
5
